Skip to main content

Table 4 Cox proportional-hazards regression model for distant-metastasis-free survival (DMFS) and breast-cancer-specific survival (BCSS) in 692 patients with tissue HER2-positive breast cancer

From: Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer

Variable

DMFS

BCSS

 

HR

95% CI

P

HR

95% CI

P

Model with dichotomized serum HER2 ECD level, elevated vs normal

Serum HER2 ECD level, >15.2 ng/ml

3.788

2.034–7.054

<0.001a

2.564

1.230–5.343

0.012a

Tumor size, >2 cm

1.731

0.859–3.487

0.125

1.134

0.515–2.497

0.754

Lymph node positive

2.614

1.011–6.756

0.047a

2.428

0.812–7.257

0.112

Grade 3+

1.972

1.069–3.638

0.030a

1.575

0.758–3.270

0.223

Lymphovascular invasion

2.625

1.419–4.855

0.002a

2.740

1.315–5.709

0.007a

Chemotherapy, yes

0.235

0.081–0.687

0.008a

0.303

0.085–1.078

0.065

Hormone therapy, yes

1.576

0.841–2.951

0.156

1.032

0.494–2.156

0.933

Trastuzumab, received

1.734

0.902–3.332

0.099

1.969

0.903–4.292

0.089

Model with four subgroups classified by serum HER2 ECD levels, each quartile group vs lowest-quartile subgroup

Serum HER2 ECD level,

 Lowest quartile (reference)

1

  

1

  

 Second quartile

1.827

0.549–6.078

0.326

1.008

0.224–4.529

0.992

 Third quartile

3.029

1.003–9.152

0.049a

2.407

0.669–8.655

0.179

 Highest quartile

4.746

1.591–14.160

0.005a

2.826

0.785–10.176

0.112

Tumor size, >2 cm

1.741

0.864–3.507

0.121

1.146

0.519–2.534

0.736

Lymph node positive

2.502

0.982–6.376

0.055

2.407

0.804–7.211

0.117

Grade 3+

1.844

1.010–3.370

0.046a

1.844

1.010–3.370

0.046a

Lymphovascular invasion

2.303

1.250–4.240

0.007a

2.550

1.223–5.317

0.012a

Chemotherapy, yes

0.210

0.074–0.599

0.004a

0.273

0.078–0.957

0.042a

Hormone therapy, yes

1.443

0.784–2.655

0.238

1.038

0.501–2.150

0.920

Trastuzumab, received

1.930

1.013–3.677

0.045a

2.098

0.968–4.549

0.061

  1. aSignificant at P < 0.05.